Review explores the effectiveness of potassium-competitive acid blockers in treating foregut diseases, suggesting potential benefits over traditional therapies.
Purpose of review The purpose of this review is to explore the current clinical evidence evaluating the use of potassium-competitive acid blockers (PCABs) in the management of foregut diseases. Recent findings PCABs have been shown to have clinical superiority over proton pump inhibitors in the management of H. pylori and Los Angeles grade C/D erosive esophagitis. PCABs also are approved for use in nonerosive reflux disease, and data suggest a possible use in peptic ulcer disease. Summary There is utility of PCABs in the management of multiple foregut diseases. More data are required to understand the utility of PCABs in the management of Barett's esophagus and eosinophilic esophagitis.
No takes yet. Share an insight, caveat, or question.
Ghai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: